Samsara Biocapital, Llc
- Regulatory AUM
- $2.2B
- Discretionary
- $2.2B
- Clients
- 3
- Avg AUM / client
- $723M
- Accounts
- 3
- Employees
- 31
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Jun 26, 2026
Investments (13F portfolio — 22 positions, $1,029,103,106)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Scholar Rock Hldg Corp | COM | $339,088,572 | 6,897,652 | 32.9% | 15.6% |
| 2 | Mineralys Therapeutics Inc | COM | $159,045,878 | 5,871,018 | 15.5% | 7.33% |
| 3 | Alumis Inc | COM | $139,785,175 | 6,345,219 | 13.6% | 6.44% |
| 4 | Septerna Inc | COM | $75,673,546 | 3,149,128 | 7.35% | 3.49% |
| 5 | Kalaris Therapeutics Inc | COM | $74,710,427 | 12,948,081 | 7.26% | 3.44% |
| 6 | Spyglass Pharma Inc | COM SHS | $54,668,882 | 2,109,953 | 5.31% | 2.52% |
| 7 | Neurogene Inc | COM | $34,617,280 | 1,717,127 | 3.36% | 1.6% |
| 8 | Inventiva Sa | ADS | $28,831,168 | 5,194,805 | 2.8% | 1.33% |
| 9 | Sutro Biopharma Inc | COM SHS | $26,476,142 | 1,062,872 | 2.57% | 1.22% |
| 10 | Jade Biosciences Inc | COM NEW | $13,611,612 | 968,798 | 1.32% | 0.63% |
| 11 | Vtv Therapeutics Inc | CL A NEW | $11,838,351 | 298,496 | 1.15% | 0.55% |
| 12 | Aquestive Therapeutics Inc | COM | $10,375,000 | 2,500,000 | 1.01% | 0.48% |
| 13 | X4 Pharmaceuticals Inc | COM NEW | $7,568,498 | 1,832,566 | 0.74% | 0.35% |
| 14 | Nkarta Inc | COM | $7,401,175 | 3,507,666 | 0.72% | 0.34% |
| 15 | Arcellx Inc | COMMON STOCK | $6,989,438 | 60,873 | 0.68% | 0.32% |
| 16 | Upstream Bio Inc | COM | $6,624,423 | 736,047 | 0.64% | 0.31% |
| 17 | Abivax Sa | SPONSORED ADS | $6,300,294 | 56,581 | 0.61% | 0.29% |
| 18 | Agomab Therapeutics Nv | SPONSORED ADS | $6,294,000 | 600,000 | 0.61% | 0.29% |
| 19 | Rani Therapeutics Hldgs Inc | COM CL A | $6,245,800 | 8,500,000 | 0.61% | 0.29% |
| 20 | Coherus Oncology Inc | COM | $5,794,285 | 3,428,571 | 0.56% | 0.27% |
| 21 | Palvella Therapeutics Inc Ne | COM | $4,790,549 | 38,432 | 0.47% | 0.22% |
| 22 | Gossamer Bio Inc | COM | $2,372,611 | 7,222,559 | 0.23% | 0.11% |
Top 25 of 22 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 3 | $2.2B | 100.0% |
Private funds (3)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $1.7B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Samsara Biocapital, L.P. master | Venture Capital Fund | Delaware | $1.6B | 154 |
| Smsr B1, L.P. feeder | Venture Capital Fund | Cayman Islands | $121M | 1 |
| 565 Spv I, L.P. | Venture Capital Fund | Delaware | $11.3K | 8 |
People (4)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Akkaraju, Srinivas | Manager Of Samsara Biocapital, Llc | Sep 2016 (10y) | 75% or more | |
| Dybbs, Michael, Philip | Partner | Feb 2017 (10y) | Less than 5% | |
| Ahmad, Miran, Nasruddin | Chief Financial Officer | Jan 2023 (4y) | Less than 5% | |
| Hussain, Abrar, Ahmed | General Counsel And Chief Compliance Officer | Jan 2023 (4y) | Less than 5% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (3, $1.7B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Samsara Biocapital, L.P. | Venture Capital Fund | $1.6B | $50.0K | 154 |
| Smsr B1, L.P. | Venture Capital Fund | $121M | $0 | 1 |
| 565 Spv I, L.P. | Venture Capital Fund | $11.3K | $30.0K | 8 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 06/26/2026 | 1.58 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Jun 26, 2026.
View current Form ADV (SEC/IAPD) ↗